Company intelligence / Profile preview

Viva Bio Pharma Services

Shanghai, Shanghai, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~2600
Development stage: Phase 2

Overview

As of June 2024, Viva Biotech has provided R&D and manufacturing services to over 2,350 biotech/pharma clients globally. They have invested in/incubated more than 90 biotech startups via their equity-for-service model. Their integrated CRO/CDMO business continues to grow with significant expansion into new technologies such as AI-driven drug discovery platforms

Modalities: Small moleculeMonoclonal antibodyPeptidesNucleic acid-based drugs
Industry: Contract Research Organization

Partnerships

Temasek Holdings (investment partner)Highlight Capital (investment partner)Numerous global biopharma/biotech companies (CRO/CDMO service clients)

Beyond the preview

Go deeper on Viva Bio Pharma Services.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viva Bio Pharma Services.

Explore the full profile